The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Ozempic works by mimicking the hormone GLP-1, which suppresses hunger and regulates blood sugar levels. All semaglutide ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.